Group 1 - The core viewpoint of the article is that Guangyuyuan (600771) has clarified its relationship with Beijing Futai Henglai Technology Co., Ltd., which is authorized to use its trademark for store operations [1] - The company emphasizes that the relationship with the licensee is based on product distribution and complies with regulatory approval procedures [1] - Guangyuyuan plans to strengthen brand authorization management, enhance daily supervision, conduct regular evaluations, and continue promoting brand standardization efforts to protect its brand image and interests [1]

Core Viewpoint - The article discusses the controversy surrounding "Antarctic krill oil" products linked to Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., which has led to regulatory investigations and significant brand management actions by the company [1][5][9]. Group 1: Regulatory Actions - The Chengdu New District Market Supervision Administration has established a joint investigation team to look into the "Antarctic krill oil" incident, with the case currently under investigation [1]. - The company has been ordered to stop the sale of the implicated products and is required to compensate consumers as per regulatory guidelines [5]. Group 2: Company Response - Beijing Tongrentang Group issued an apology for the damage caused to consumers and initiated a zero-tolerance brand management action, including a comprehensive investigation of the involved products [5]. - The company is pursuing legal action against the involved parties for trademark infringement and misleading consumers regarding the use of the "Beijing Tongrentang" name [9]. Group 3: Product Quality Concerns - A product marketed as "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" was found to have a phospholipid content of 0, raising concerns about product authenticity [7]. - The product was not directly produced by Beijing Tongrentang but was distributed by its subsidiary, which has been criticized for its brand management and quality control practices [9]. Group 4: Brand Reputation - Beijing Tongrentang, a historic brand established in 1669, has faced multiple trust crises due to issues related to brand licensing and quality control of its subsidiary products [9].

Core Viewpoint - Tongrentang Group issued an apology regarding the controversy over "Antarctic krill oil," acknowledging consumer rights damage and committing to a zero-tolerance brand management initiative [1] Group 1: Company Actions - The company has initiated a special task force to conduct a thorough investigation of the implicated products in Sichuan, ensuring a comprehensive inquiry [1] - The company has ordered the immediate removal of the implicated products from the market and will supervise compliance with regulatory requirements for consumer compensation [1] - Legal actions will be pursued against Sichuan Health, Habao Pharmaceutical, and related e-commerce platforms for trademark infringement and misleading practices [1] Group 2: Product Investigation - The Shanghai Consumer Protection Commission tested 15 popular Antarctic krill oil products, revealing that one product labeled as "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" had a phospholipid content of 0, indicating potential fraud [4] - The implicated product was not directly produced by Beijing Tongrentang but was distributed by its subsidiary, Sichuan Health Pharmaceutical, with production outsourced to Anhui Habao Pharmaceutical, representing a typical private label model [7] Group 3: Brand Management Issues - The product in question was produced without authorization to prominently feature the "Beijing Tongrentang" name, leading to legal proceedings initiated by the company against the involved entities [7] - Beijing Tongrentang, the sole legal holder of the "Tongrentang" trademark, has faced trust issues due to repeated incidents of private label mismanagement, raising concerns about brand authorization and quality control [7]

Core Viewpoint - Tongrentang Group has issued an apology regarding the recent controversy over "Antarctic krill oil," acknowledging the damage caused to consumer rights and committing to a zero-tolerance approach towards brand management [1] Group 1: Company Response - Tongrentang Group has initiated a special action for strict brand management, deploying a task force to Sichuan for a comprehensive investigation of the involved products [1] - The company has ordered the immediate removal of the implicated products from the market and is ensuring compliance with regulatory requirements for consumer compensation [1] - Legal actions will be pursued against Sichuan Health, Habao Pharmaceutical, and related e-commerce platforms for trademark infringement and misleading consumers [1] Group 2: Product Investigation - The Shanghai Consumer Protection Committee conducted tests on 15 popular Antarctic krill oil products, revealing that the "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" had a phospholipid content of 0, indicating potential fraud [3] - The implicated product was not directly produced by Beijing Tongrentang but was distributed by its subsidiary, Sichuan Health Pharmaceutical, with manufacturing outsourced to Habao Pharmaceutical [5] Group 3: Brand Management Issues - Habao Pharmaceutical admitted to not adding the claimed "Antarctic krill oil" during production, and the product packaging was created per the requirements of Sichuan Health Pharmaceutical [5] - The unauthorized use of the "Beijing Tongrentang" name on the product has led to legal proceedings initiated by the company against the involved parties [5] - There are concerns within the industry regarding Tongrentang's brand authorization management and quality control of its subsidiary products, which have contributed to a decline in consumer trust [6]

Core Viewpoint - The scandal surrounding Antarctic krill oil has highlighted the branding issues and quality control failures associated with Tongrentang, a well-known traditional Chinese medicine brand [2][4][11]. Group 1: Incident Overview - The Shanghai Consumer Protection Commission conducted tests on 15 popular Antarctic krill oil products, revealing that a product labeled as "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" contained 0% phospholipid, indicating potential fraud [2][5]. - The implicated product was not directly produced by Beijing Tongrentang but was distributed by its subsidiary, Sichuan Health Pharmaceutical Co., Ltd., with manufacturing outsourced to Anhui Habio Pharmaceutical Co., Ltd., exemplifying a typical private label model [2][4]. - Following the investigation, both the distributor and manufacturer were summoned by the Shanghai Consumer Protection Commission, with Habio admitting to not including the claimed Antarctic krill oil in the production process [6][8]. Group 2: Brand Trust Crisis - Beijing Tongrentang, established in 1669, has faced multiple trust crises due to private label issues, leading to concerns about its brand management and quality control [4][11]. - The Antarctic krill oil market has seen a surge in popularity, but the wide price range and varying quality have made it difficult for consumers to discern reliable products [5][11]. - Experts suggest that the brand's response, which includes legal action against the involved companies and a reminder for consumers to verify the authenticity of the "Double Dragon" trademark, may not fully alleviate public skepticism [9][11]. Group 3: Regulatory and Compliance Issues - The Shanghai Consumer Protection Commission has urged Sichuan Health Pharmaceutical to conduct a self-examination, apologize to consumers, and recall the problematic products [8][12]. - The incident has raised questions about the accountability of Beijing Tongrentang regarding its subsidiaries and the need for clearer brand management and authorization boundaries [11][12]. - Experts recommend that Beijing Tongrentang establish a comprehensive quality control and traceability system to prevent future issues, including stricter oversight of its subsidiaries and private label products [13][15]. Group 4: Manufacturer's Legal Troubles - Anhui Habio Pharmaceutical, the manufacturer of the disputed krill oil, has been involved in multiple legal disputes, including trademark infringement cases, indicating a pattern of compliance issues [14][15]. - The company has faced administrative penalties for various violations, highlighting the need for a robust compliance framework to ensure product quality and legal adherence [15].

Core Viewpoint - Wuliangye Group has identified unauthorized stores selling its products on various online platforms, which disrupts normal sales order and poses risks to consumer rights [1] Group 1: Company Actions - The company released a notice to consumers listing 46 unauthorized stores across platforms like Douyin, JD.com, Kuaishou, Meituan, Pinduoduo, and Tmall [1] - Wuliangye Group recommends consumers purchase products through official channels listed on its website to ensure authenticity and quality [1] Group 2: Consumer Guidance - Consumers are advised to request invoices and purchase receipts to facilitate future verification of product authenticity [1] - The notice emphasizes the importance of buying from authorized sources to avoid potential risks associated with unauthorized sales [1]